Patient-reported outcome instrument selection: Designing a measurement strategy

Value in Health

Volumn 10, Issue SUPPL. 2, 2007, Pages

  Snyder, Claire F ^b   Watson, Maria E ^c   Jackson, Joseph D ^d   Cella, David ^e   Halyard, Michele Y ^f   Sloan, Jeff A ^a  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f MAYO CLINIC   (United States)

Author keywords

Instrument selection; Patient reported outcomes; Validation

Indexed keywords

CONCEPTUAL FRAMEWORK; CONFERENCE PAPER; FOOD AND DRUG ADMINISTRATION; INSTRUMENT VALIDATION; OUTCOMES RESEARCH; PATIENT REPORTDE OUTCOMES; PRIORITY JOURNAL; RELIABILITY; UNITED STATES;

EID: 36048938965     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00270.x     Document Type: Conference Paper

References (26)

1. Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims (DRAFT). US Department of Health and Human Services Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER); Center for Devices and Radiological Health (CDRH), February 2006. Available from: http://www.fda.gov/cder/guidance/ 5460dft.htm [Accessed May 18, 2007].
2. Mayo/FDA Patient-Reported Outcome Meeting. Chantilly, VA, February 2006.
3. Rothman M, Beltran P, Cappelleri JC, et al. Mayo/FDA Patient-Reported Outcomes Consensus Writing Group. Patient reported outcomes: conceptual issues. Value Health 2007 10 (Suppl. 2 S66 75.
4. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999 282 : 790 5.
5. Jaeschke RJ, Singer J, Guyatt GH. Ascertaining the minimal clinically important difference. Control Clin Trial 1989 10 : 407 15.
6. Detsky AD, Sackett DL. When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med 1985 145 : 709 12.
7. Naylor CD, Llewellyn-Thomas HA. Can there be a more patient-centered approach to determining clinically important effect sizes for randomized treatment trials? J Clin Epid 1994 47 : 787 95.
8. Burke L. Acceptable evidence for pharmaceutical advertising and labeling. DIA Workshop on Pharmacoeconomic and Quality of Life Labeling and Marketing Claims, October 2000.
9. Hahn EA, Cella D, Chassany O, et al. A. guide for clinicians to compare the precision of health-related quality of life data relative to other clinical measures. Mayo Clinic Proc (in press).
10. Santanello NC, Baker D, Cappelleri JC, et al. Regulatory issues for health-related quality of life - PhRMA Health Outcomes Committee Workshop, 1999. Value Health 2002 5 : 14 25.
11. Damiano AM, Snyder C, Strausser B, Willian MK. A review of health-related quality-of-life concepts and measures for Parkinson's disease. Qual Life Res 1999 8 : 235 43.
12. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002 11 : 193 205.
13. Frost MH, Reeve BB, Liepa AM, et al. Mayo/FDA Patient-Reported Outcomes Consensus Writing Group. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health 2007 10 (Suppl. 2 S94 105.
14. Food and Drug Administration. Advair information. Thomson's Physician Desk Reference, 2006.
15. Mathias SD, Colwell HH, Miller DP, et al. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000 22 : 128 39.
16. Food and Drug Administration. Enbrel information. Physician Desk Reference (60th ed.) Thomson, 2006.
17. Caro G, Caro JJ, O'Brien JA, et al. The bother assessment in skin conditions (BASC) scale: Redefining quality of life measures in dermatology. American Academy of Dermatology Annual Meeting 1996.
18. Food and Drug Administration. Vaniqa information. Thompson's Physician Desk Reference, 2006.
19. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 49 : 822 30.
20. Food and Drug Administration. Viagra information. Thomson's Physician Desk Reference, 2006.
21. Turner R, Quittner AL, Parasuraman BM, et al. Mayo/FDA Patient-Reported Outcomes Consensus Writing Group. Patient-reported outcomes: instrument development and selection issues. Value Health 2007 10 (Suppl. 2 S86 93.
22. Damiano AM, McGrath MM, Willian MK, et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 2000 9 : 87 100.
23. Gotay CC, Lipscomb J, Snyder CF. Reflections on findings of the cancer outcomes measurement working group: moving to the next phase. J Natl Cancer Inst 2005 97 : 1568 74.
24. Stephenson NL, Herman J. Pain measurement: a comparison using horizontal and vertical visual analogue scales. Appl Nurs Res 2000 13 : 157 8.
25. Ware JE. SF-36® Health Survey update. Available from: http://www.sf-36.org/tools/sf36.shtml [Accessed March 14, 2007].
26. Guyatt G. The switch from paper. DIA Workshop on Benefits and Challenges with ePRO: Outcomes and Endpoints as We Emerge from the Long Age of Paper Methods, April 2005.